RxDoctor Payments Data

Michael Brunt, MD

Cardiovascular Disease · Marietta, GANPI 1063859171

Payments from drug & device makers

$3,144in general payments, 2019–2025

Across 69 payments — averaging $45.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Applied Medical Resources Corporation$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$283
  • Abbott$234
  • Boston Scientific$212
  • Novartis$184
  • AstraZeneca$137
  • plus $968 from 15 others

What the payments were for

  • Consulting fees$1,12536%
  • Food & beverage$1,91961%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,144 in reported general payments places this provider in the 55th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$193,763
Medicare patients
1,895
Services billed
4,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban359$375,846
JardianceEmpagliflozin73$90,672
EntrestoSacubitril/Valsartan81$87,453
FarxigaDapagliflozin Propanediol100$85,352
XareltoRivaroxaban32$36,178
BrilintaTicagrelor11$7,131
NexlizetBempedoic Acid/Ezetimibe13$5,213
Rosuvastatin Calcium356$4,747
Metoprolol Succinate263$3,868
Ezetimibe103$3,008
Atorvastatin Calcium360$2,917
Losartan Potassium246$2,035
Carvedilol231$1,768
Amlodipine Besylate294$1,586
Hydralazine Hcl75$1,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$375,846359 claims
AstraZenecaFarxiga, Brilinta$137$92,483111 claims
Boehringer IngelheimJardiance$18$90,67273 claims
NovartisEntresto$184$87,45381 claims
Johnson & JohnsonXarelto$40$36,17832 claims
Esperion Therapeutics, Inc.Nexlizet$48$5,21313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →